# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The majority of trial sites have been opened and patient enrollment is progressing with the SERENITY At-Home trial of BXCL501 f...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the pr...
- SEC Filing
B of A Securities analyst Geoff Meacham downgrades BioXcel Therapeutics (NASDAQ:BTAI) from Buy to Underperform and lowers th...
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price targe...